Ipamorelin For Sale — Research Vials and the CJC-1295 / Ipamorelin Blend

What Is Ipamorelin?

Ipamorelin emerged from a medicinal-chemistry programme that set out to strip the growth hormone releasing peptide pharmacophore down to its minimum active elements. The result is a five-residue molecule containing two D-amino acids and a non-proteinogenic residue, features that both confer protease resistance and lock the peptide into the conformation that GHS-R1a recognises.

The receptor it targets, GHS-R1a, is a class A GPCR that couples to Gq and signals through phospholipase C, inositol trisphosphate, and intracellular calcium mobilisation. That distinguishes it mechanistically from the GHRH receptor, which is a class B receptor signalling through Gs and cAMP — an important distinction when designing an assay, because the two arms require different readouts.

Selectivity is the reason ipamorelin persists in the literature. Older peptides in the same family activate additional pathways that confound interpretation of a growth-hormone-axis experiment. Ipamorelin's cleaner profile means an observed calcium response in a GHS-R1a line can be attributed to that receptor with more confidence.

GHS-R1a Signalling and the GHRH Axis

In cell-based work, ipamorelin is characterised by intracellular calcium flux and inositol phosphate accumulation in GHS-R1a-expressing lines, typically read on a fluorescent plate reader with a ghrelin positive control. Receptor constitutive activity is a known feature of GHS-R1a, so a properly controlled experiment measures baseline signal in the absence of agonist as well.

CJC-1295 works on the other side of the axis. It is a modified GHRH(1-29) analog with substitutions that resist DPP-4 cleavage; the No-DAC variant lacks the drug-affinity-complex linker and therefore does not covalently bind albumin, giving it a much shorter profile. It signals through cAMP at the class B GHRH receptor.

The combination is studied because the two receptors are physiologically complementary: pituitary somatotroph models respond to GHRH-receptor and GHS-R1a stimulation differently, and combined engagement produces responses that neither arm reproduces alone. Any study making that claim needs all four arms — vehicle, each peptide alone, and the combination.

Standalone Vials vs. the CJC-1295 / Ipamorelin Blend

Buy standalone vials when the experimental design requires independent control of each arm. Dose-ratio work, receptor-selectivity profiling, and any study intending to demonstrate synergy all require the two peptides to be titrated separately; a fixed-ratio blend cannot support those designs.

The co-formulated blend is appropriate when the combination is treated as a single test article — screening work, comparative panels against other secretagogue stacks, and stability studies of the combination itself. It eliminates the ratio error that creeps in when two peptides are reconstituted and mixed by hand under time pressure.

A practical note: the two components have different solubility and different stability windows, so a blend should be treated as having the shorter of the two working windows rather than the longer. Document the preparation date and treat it conservatively.

Research Applications

The dominant in vitro application is pituitary and somatotroph cell-culture work, measuring calcium mobilisation, cAMP, and growth-hormone release into the culture supernatant by immunoassay. Ipamorelin serves as the selective GHS-R1a arm and ghrelin as the endogenous reference agonist.

Receptor-pharmacology laboratories use ipamorelin in binding-displacement panels and in biased-signalling studies, comparing calcium and β-arrestin readouts to characterise whether a novel secretagogue behaves like ipamorelin or like the less selective GHRP compounds.

Comparative panels are again common: ipamorelin against hexarelin, GHRP-2, GHRP-6 and sermorelin covers the practical range of secretagogue pharmacology, and running them together with shared controls is the only way to make cross-compound potency statements defensible.

• Somatotroph culture GH-release and calcium assays
• GHS-R1a binding, displacement and biased-signalling panels
• Comparative screens against hexarelin, GHRP-2 and GHRP-6
• Combination studies with GHRH-receptor agonists

Storage and Reconstitution

Ipamorelin is a small, robust peptide, but the lyophilized cake is still hygroscopic and should be stored frozen, sealed, and away from light. Let vials warm to room temperature before opening; opening a cold vial draws humid air onto the cake and is the most common cause of dissolution problems.

Reconstitute with bacteriostatic water directed at the vial wall and swirl until clear. A five-residue peptide dissolves quickly and should not need agitation. Because ipamorelin's working concentrations are often in the low microgram-per-millilitre range, a reconstitution calculator is worth using rather than estimating.

Reconstituted solution should be refrigerated at 2–8 °C, dated, and used within a short window. For blends containing CJC-1295, apply the more conservative of the two stability windows and aliquot at preparation so that the combination is never subjected to repeated freeze-thaw cycling.

Material Specifications

Compound

Ipamorelin (pentapeptide GHS-R1a agonist)

Sequence

Aib-His-D-2-Nal-D-Phe-Lys-NH2

Molecular formula

C38H49N9O5

Molar mass

≈ 711.9 g/mol

Primary target

Growth hormone secretagogue receptor 1a (ghrelin receptor)

Purity

≥ 99% by reverse-phase HPLC

Storage

Sealed vials frozen; reconstituted 2–8 °C

Use

In vitro laboratory research only

Purity, Testing & Certificates of Analysis

Ipamorelin is released against reverse-phase HPLC purity criteria with mass-spectrometry identity confirmation. Because the sequence contains D-amino acids and a non-proteinogenic residue, the identity check matters as much as the purity number: a correct mass with an incorrect stereochemical profile is the failure mode that a purity percentage alone would not reveal.

The CJC-1295 / Ipamorelin blend is additionally reviewed to confirm both components are present and chromatographically resolvable at release, so that the stated ratio is verifiable rather than assumed.

Each shipment references a dated, lot-specific Certificate of Analysis covering purity, identity, water content, appearance and assay date, retrievable after purchase for study documentation.

Browse the Certificate of Analysis library →

Research FAQ

Research Resources

• Ipamorelin in the Peptide Encyclopedia
• CJC-1295 + Ipamorelin encyclopedia entry
• Ipamorelin vs. Sermorelin comparison
• Guide: growth hormone secretagogues
• Guide: storage and handling protocols
• Reconstitution calculator
• Peptide Encyclopedia